Asian markets ended mostly higher on Monday on investors' optimism over swift global economic recovery after the US House of Representatives passed President Joe Biden’s $1.9 trillion corona virus relief package early Saturday. Further, optimism over Covid-19 vaccine rollouts too supporting market sentiments. Johnson & Johnson's single-dose Covid-19 vaccine was given the green light by the United States Food and Drug Administration (USFDA) on Saturday for emergency use purposes. Chinese shares ended up despite reports that China’s factory activity grew in February at a slower pace than a month earlier. The latest survey from Caixin showed that the manufacturing sector in China continued to expand in February, albeit at a slower pace with a manufacturing PMI score of 50.9, down from 51.5 in January. Moreover, Japanese stocks settled with strong gains after a survey showed that Japan climbed into expansion territory in February with a 22-month high manufacturing PMI score of 51.4, while the corona virus related state of emergency was lifted in six prefectures outside the Tokyo region amid signs of an improvement in the infection situation too kept the sentiments positive. Meanwhile, markets in South Korea and Taiwan were closed for holidays.
Asian Indices | Last Trade | Change in Points | Change in % |
Shanghai Composite | 3,551.40 | 42.32 | 1.21 |
Hang Seng | 29,452.57 | 472.36 | 1.63 |
Jakarta Composite | 6,338.51 | 96.71 | 1.55 |
KLSE Composite | 1,567.14 | -10.61 | -0.67 |
Nikkei 225 | 29,663.50 | 697.49 | 2.41 |
Straits Times | 2,973.00 | 23.96 | 0.81 |
KOSPI Composite | - | - | - |
Taiwan Weighted | - | - | - |
Start Research-backed Investing ...Now. Subscribe to Sapphire
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: